Esperite NV (ESP) with The Cell Factory has signed the agreement with the PHARM CRO to start preparation for the first-in-man clinical trials in treatment of Crohn’s disease.

May 17, 2018 Group News

Esperite NV (ESP) with The Cell Factory has signed the agreement with the PHARM CRO to start preparation for the first-in-man clinical trials in treatment of Crohn’s disease.

Amsterdam, The Netherlands – 17 May 2018

read more

Esperite’s (ESP) The Cell Factory received European funding to develop the 2nd generation EVs drug for treatment of Stroke

May 3, 2018 Group News

Esperite’s biotech company The Cell Factory, Belgium has received funding from the European Union’s Horizon 2020 research and innovation Programme for development and characterization of the extracellular vesicles (EVs) drug CF-MEV-126 for treatment of stroke. The project is focused on the development of the 2nd generation EVs drug, with enhanced anti-inflammatory and neuroprotective activities.

Amsterdam, The Netherlands – 3 May 2018

read more